Ricevi le ultime notizie sulle azioni Personalis con aggiornamenti su tendenze di mercato, dati finanziari e analisi di Benzinga. Rimani informato sulle performance di PSNL

Ultime notizie per

PERSONALIS INC

Personalis

Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.

Jim Cramer- AI Is Bigger Than Rate Cuts

Long Ideas

News

Markets

Media

Trading Ideas

INSM

OUST

PAAS

PSNL

TSLA

Un&#39;azione mineraria brilla sul mercato, ma il noto analista frena gli entusiasmi. Non sempre un rialzo è un buon segnale d&#39;acquisto.

Questo titolo sale del 5%, ma per Jim Cramer non è quello giusto

Personalis Inc

Press Releases

Personalis Expands Tempus Strategic Collaboration to Bring Ultra-Sensitive Cancer Recurrence Testing to Colorectal Cancer Patients

Small Cap

Opinion

From Clinics to Cancer Labs, AI Is Unlocking a New $100B+ Era in Medicine

Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Personalis to Announce Second Quarter 2025 Financial Results

Personalis Reports Second Quarter 2025 Financial Results

Personalis to Participate in Upcoming Investor Conferences

Personalis Announces New Data from a Landmark Neoadjuvant Lung Cancer Trial Showing Superiority of Ultra-Sensitive, Tumor-Informed MRD Testing

CATE Clinical Trial Launched to Demonstrate the Clinical Utility of ctDNA-Guided Treatment in Breast Cancer Using the Ultrasensitive NeXT Personal Test

Personalis Announces New Data from a Landmark Lung Cancer Trial Utilizing Ultrasensitive MRD Testing

AVAI

MSFT

TVGN

AbCellera Biologics

Adaptive Biotechnologies Corporation - Common Stock

Adaptive Biotechnologies

Azenta

Bio-Rad Laboratories, Inc. Class A Common Stock

Bio-Rad Laboratories

BioLife Solutions

Bruker

Bruker Corporation - 6.375% Mandatory Convertible Preferred Stock, Series A

Codexis

Cytek Biosciences

CryoPort

Ginkgo Bioworks Holdings, Inc. Class A Common Stock

Ginkgo Bioworks Holdings

Evotec SE - American Depositary Shares each representing 1/2 of one ordinary share

Evotec

Fortrea Holdings

Standard BioTools

Lifecore Biomedical

Mesa Laboratories

Maravai LifeSciences Holdings, Inc. - Class A common stock

Maravai LifeSciences

Niagen Bioscience

Pacific Biosciences of California, Inc. - Common Stock

Pacific Biosciences

Quantum-Si Incorporated - Class A Common Stock

Quantum-Si

Quanterix

Sotera Health

Stevanato Group

Alpha Teknova

10x Genomics

HC Wainwright & Co.

Needham

Craig-Hallum

Lake Street

BTIG

Comments

Personalis Notizie sulle azioni

Notizie

Ultime notizie per

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO